β‐Sitosterol attenuates anlotinib resistance in non‐small cell lung cancer cells by inhibiting miR‐181a‐3p/SHQ1 signaling

• Published in: Chemical biology & drug design Vol. 103; no. 3; pp. e14493 - n/a
• Main Authors: Wang, Li‐huai, Sun, Yin‐hui, Liu, Hua, Yang, Xiao, Wen, Zhi, Tian, Xue‐fei
• Format: Journal Article
• Language: English
• Published: England 01.03.2024
• Subjects: Anlotinib; apoptosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Drug Resistance, Neoplasm - drug effects; Endoplasmic Reticulum Chaperone BiP; Humans; Indoles; Intracellular Signaling Peptides and Proteins; lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; MicroRNAs - drug effects; MicroRNAs - genetics; miR‐181a‐3p; proliferation; Quinolines; SHQ1/UPR signaling; Sitosterols; β‐Sitosterol; lung cancer; Anlotinib; β-Sitosterol; miR-181a-3p; proliferation; SHQ1/UPR signaling; apoptosis

Anlotinib is used for the treatment of advanced non‐small cell lung cancer; however, the emergence of drug resistance limits its clinical application. β‐sitosterol may also be used to treat lung cancer, but there have been no studies evaluating β‐sitosterol against anlotinib‐resistant lung cancer. T...